金域医学
(603882)
| 流通市值：129.07亿 | | | 总市值：130.55亿 |
| 流通股本：4.58亿 | | | 总股本：4.63亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,884,285,424.41 | 1,350,977,738.08 | 6,030,452,713.41 | 4,538,151,376.33 |
| 营业收入 | 2,884,285,424.41 | 1,350,977,738.08 | 6,030,452,713.41 | 4,538,151,376.33 |
| 二、营业总成本 | 2,656,077,919.64 | 1,292,025,224.52 | 5,814,342,183.77 | 4,282,602,888.45 |
| 营业成本 | 1,825,393,044.67 | 879,542,359.95 | 3,935,421,700.54 | 2,957,942,145.78 |
| 税金及附加 | 7,196,397.79 | 3,404,676.35 | 13,941,270.62 | 9,785,427.36 |
| 销售费用 | 383,665,349.9 | 191,273,237.47 | 874,424,657.13 | 639,144,257.81 |
| 管理费用 | 280,870,507.84 | 142,403,701.5 | 653,032,094.53 | 433,763,158.78 |
| 研发费用 | 157,022,130 | 74,286,699.22 | 341,275,805.95 | 243,155,334.32 |
| 财务费用 | 1,930,489.44 | 1,114,550.03 | -3,753,345 | -1,187,435.6 |
| 其中:利息费用 | 6,190,252.84 | 3,348,412.07 | 14,681,872.11 | 11,553,789.31 |
| 其中:利息收入 | 5,391,658.56 | 2,875,482.62 | 20,507,949.69 | 14,349,344.91 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -10,393,882.88 | -7,879,719.32 | -2,124,860.34 | - |
| 加:投资收益 | 3,477,813.85 | 1,516,128.97 | 3,838,869.54 | 3,657,566.25 |
| 汇兑收益 | - | - | - | 1,071.91 |
| 资产处置收益 | 3,444,177.63 | 620,159.6 | 4,398,060.89 | 2,663,415.74 |
| 资产减值损失(新) | 44,536.78 | -375,721.11 | -11,553,941.07 | -313,381.48 |
| 信用减值损失(新) | 38,099,230.73 | 9,979,383.87 | -370,478,167.15 | -344,949,638.56 |
| 其他收益 | 5,760,842.79 | 3,456,710.04 | 29,938,718.22 | 20,386,179.36 |
| 四、营业利润 | 268,640,223.67 | 66,269,455.61 | -129,870,790.27 | -63,006,298.9 |
| 加:营业外收入 | 994,686.38 | 334,668.45 | 2,832,726.67 | 1,670,128.53 |
| 减:营业外支出 | 12,311,691.02 | 5,531,292.2 | 54,572,970.57 | 20,781,600.11 |
| 五、利润总额 | 257,323,219.03 | 61,072,831.86 | -181,611,034.17 | -82,117,770.48 |
| 减:所得税费用 | 45,701,340.69 | 13,190,076.98 | -3,010,203.46 | 6,676,306.45 |
| 六、净利润 | 211,621,878.34 | 47,882,754.88 | -178,600,830.71 | -88,794,076.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 211,621,878.34 | 47,882,754.88 | -178,600,830.71 | -88,794,076.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 190,192,822.54 | 42,790,549.78 | -173,243,555.22 | -79,609,540.75 |
| 少数股东损益 | 21,429,055.8 | 5,092,205.1 | -5,357,275.49 | -9,184,536.18 |
| 扣除非经常损益后的净利润 | 203,157,557.21 | 51,838,135.77 | -160,703,492.04 | -84,249,682.13 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 0.09 | -0.37 | -0.17 |
| (二)稀释每股收益 | 0.41 | 0.09 | -0.37 | -0.17 |
| 八、其他综合收益 | -24,165,066.37 | -15,756,437.56 | -13,554,392.73 | -8,139,141.33 |
| 归属于母公司股东的其他综合收益 | -24,165,066.37 | -15,756,437.56 | -13,554,392.73 | -8,139,141.33 |
| 九、综合收益总额 | 187,456,811.97 | 32,126,317.32 | -192,155,223.44 | -96,933,218.26 |
| 归属于母公司股东的综合收益总额 | 166,027,756.17 | 27,034,112.22 | -186,797,947.95 | -87,748,682.08 |
| 归属于少数股东的综合收益总额 | 21,429,055.8 | 5,092,205.1 | -5,357,275.49 | -9,184,536.18 |
| 公告日期 | 2026-08-25 | 2026-04-25 | 2026-04-25 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |